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1he Ultimate Solution to the
roblem of Aspirin Resistance
n their State-of-the-Art paper, Gasparyan et al. (1) provide an
xcellent review of the potential factors responsible for aspirin
esistance. As they point out, a major problem is the lack of an
ccurate, reproducible, and practical quantitative test for measuring
latelet activation. All commercially available tests use the mea-
urement of the transmission of light through a suspension of
latelets or the passage of cells through a narrow aperture. Both of
hese techniques are limited in that they detect macroaggregates
ut not microaggregates of platelets. This limitation is easily
emonstrated by performing a dose-response test by adding
inearly increasing doses of a glycoprotein IIb/IIIa inhibitor such as
bciximab, eptifibatide, or tirofiban to the sample before measuring
he percent inhibition produced by the addition. When this is done
ith any of the commercially available tests and the dose is plotted
gainst the percent inhibition, the response in not linear, but
attens out at approximately 80% inhibition, which is close to the
egree of inhibition that is likely to be clinically desirable. This
roblem can be overcome if, instead of using the commercial tests,
ne uses an automatic cell counter to count individual platelets
efore and after the addition of the agonist. The percent inhibition
s the difference between the before and after counts divided by the
efore count. When a dose-response test with a glycoprotein
Ib/IIIa inhibitor is performed by using this technique, the
esponse is linear throughout the entire range of inhibition. An
deal test for platelet activation would eliminate the need for the
se of an agonist. Such a test would reflect in vivo activation at the
ime the sample was drawn. To avoid use of an agonist, it would
eed to be extremely sensitive. To allow for establishment of its
pecificity, it would need to be quantitative. When platelets
ecome activated, one of the first effects is the release of platelet
icroparticles that can be identified by flow cytometry. These
icroparticles have all of the surface markers of platelets that can
e detected with fluorescent-labeled antibodies. Because each
ctivated platelet releases large numbers of microparticles, each
ith multiple markers, a modified flow cytometer could be developed
pecifically to detect these markers on microparticles and, thus, be a
ery sensitive measure of platelet activation. Such a machine would
ave great utility as a tool for adjusting the doses of antiplatelet
herapy, detecting resistance to antiplatelet agents such as aspirin
nd clopidogrel, and in detecting early acute cardiac events.
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nteric Coating Is a Possible
ause of Aspirin Resistance
he observation that aspirin does not inhibit platelet function
s expected in some patients has been referred to as “aspirin
esistance.” The reported increased incidence of cardiovascular
vents in patients exhibiting aspirin resistance is indeed con-
erning (1,2) and highlights the importance of eliminating
odifiable etiologies. In a recent issue of the Journal, Gasparyan
t al. (3) discussed several of these causes, including poor
ompliance, nonsteroidal anti-inflammatory agents, and proton
ump inhibitors. It is also important to take note of recent
eports of incomplete suppression of platelet aggregation with
nteric-coated aspirin (4,5). In a randomized, open-label, cross-
ver study of healthy volunteers, incomplete thromboxane (TX)
2 inhibition was found to occur in 8% of the aspirin group and
4.3% of the enteric-coated aspirin group (p  0.0004) (4). In
nother study of 131 stable cardiovascular patients treated with
nteric-coated aspirin (75 mg/d), 44% of patients failed to
ttain optimal inhibition of serum TX, indicating suboptimal
nhibition of platelet COX-1 activity, and those with an
ncomplete aspirin response were more likely to demonstrate
latelet aggregation to arachidonic acid (21% vs. 3%; p  0.004)
5). These data are of increasing importance when considering
spirin resistance because many patients now receive low-dose
nteric-coated aspirin preparations for primary and secondary
revention of cardiovascular events.
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